Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;20(9):102883.
doi: 10.1016/j.autrev.2021.102883. Epub 2021 Jul 5.

Rheumatological complications of Covid 19

Affiliations
Review

Rheumatological complications of Covid 19

Hannah Zacharias et al. Autoimmun Rev. 2021 Sep.

Abstract

Introduction: COVID-19 has caused unprecedented hardships in the 21st century with more than 150 million infections. Various immunological phenomena have been described during the course of the infection, and this infection has also triggered autoimmunity. Rheumatological illnesses have been described following resolution of the acute infection; hence we sought to conduct a review of the rheumatological complications of COVID-19.

Methods: We conducted a literature search for articles relating to sequelae of COVID-19 from Jan 2020 to 30th April 2021.

Results: We found a number of reports of inflammatory arthritis after SARS-CoV-2 infection. SLE and renal disease have been described, and vasculitis also appears to be a common complication. Rhabdomyolysis and myositis has also been reported in a number of patients. We also found some evidence of large vessel vasculitis in 'long COVID' patients.

Conclusions: This review highlights a number of important complications such as inflammatory arthritis, lupus-like disease, myostis and vasculitis following SARS-CoV-2 infection.

Keywords: COVID-19; Chronic fatigue; Cytokine storm; Inflammatory arthritis; Long COVID; Systemic Lupus Erythematous; Vasculitis; Vasculopathy; Viral arthritis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Guan W., Ni Z., Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. - PMC - PubMed
    1. Wang L., Wang Y., Ye D., Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020 Jun;55(6):105948. - PMC - PubMed
    1. Nile S.H., Nile A., Qiu J., Li L., Jia X., Kai G. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66–70. [PMC free article] [PubMed] [Google Scholar] [Ref list] - PMC - PubMed
    1. Zhou Y., Fu B., Zheng X., Wang D., Zhao C., Qi Y. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev. 2020;7(6):998–1002. nwaa041. [Google Scholar] [Ref list] - PMC - PubMed
    1. Jose R.J., Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;20:S2213–S2600. doi: 10.1016/S2213-2600(20)30216-2. [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list] - DOI - PMC - PubMed